Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ.

Lancet. 2000 Dec 16;356(9247):2059-63.

PMID:
11145492
2.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH.

J Clin Oncol. 2011 Oct 10;29(29):3862-8. doi: 10.1200/JCO.2010.33.1298.

PMID:
21911720
3.

Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.

Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, Haq R, Goodwin PJ.

J Clin Oncol. 2010 Dec 10;28(35):5147-52. doi: 10.1200/JCO.2010.29.9230.

PMID:
21060031
4.

Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.

Carpenter JS, Storniolo AM, Johns S, Monahan PO, Azzouz F, Elam JL, Johnson CS, Shelton RC.

Oncologist. 2007 Jan;12(1):124-35.

5.

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.

Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM.

J Urol. 1999 Jul;162(1):98-102.

PMID:
10379749
7.

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW.

J Clin Oncol. 2006 Mar 20;24(9):1409-14.

PMID:
16505409
8.
9.

Newer antidepressants for hot flashes--should their efficacy still be up for debate?

Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Wolf S.

Menopause. 2009 Jan-Feb;16(1):184-7. doi: 10.1097/gme.0b013e31817dfd2b.

PMID:
18725865
10.

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study.

Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M.

Ann Oncol. 2007 Apr;18(4):689-93.

11.

Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial.

Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB.

Obstet Gynecol. 2005 Jan;105(1):161-6.

PMID:
15625158
12.

Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors.

Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA.

J Clin Oncol. 1998 Jul;16(7):2377-81.

PMID:
9667254
13.

Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial.

Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, Nunez R, Peterson E, Jakary S, Levine RA.

J Clin Oncol. 2010 Feb 1;28(4):634-40. doi: 10.1200/JCO.2009.23.5150.

PMID:
20038728
14.

Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.

Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ.

Lancet. 2005 Sep 3-9;366(9488):818-24.

15.

Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes.

Ensrud KE, Guthrie KA, Hohensee C, Caan B, Carpenter JS, Freeman EW, LaCroix AZ, Landis CA, Manson J, Newton KM, Otte J, Reed SD, Shifren JL, Sternfeld B, Woods NF, Joffe H.

Sleep. 2015 Jan 1;38(1):97-108. doi: 10.5665/sleep.4332.

16.

Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial.

Davari-Tanha F, Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H.

Arch Gynecol Obstet. 2016 May;293(5):1007-13. doi: 10.1007/s00404-015-3900-1.

PMID:
26437957
17.

North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.

Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL.

Menopause. 2015 Jun;22(6):627-32. doi: 10.1097/GME.0000000000000374.

18.

Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors.

Biglia N, Torta R, Roagna R, Maggiorotto F, Cacciari F, Ponzone R, Kubatzki F, Sismondi P.

Maturitas. 2005 Sep 16;52(1):78-85.

PMID:
16143229
19.

Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.

Pinkerton JV, Constantine G, Hwang E, Cheng RF; Study 3353 Investigators..

Menopause. 2013 Jan;20(1):28-37. doi: 10.1097/gme.0b013e31826421a8.

PMID:
23010882
20.

Phase III evaluation of fluoxetine for treatment of hot flashes.

Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA.

J Clin Oncol. 2002 Mar 15;20(6):1578-83.

PMID:
11896107
Items per page

Supplemental Content

Support Center